Efficacy and safety of hypertonic dextrose prolotherapy for patients with post-herpetic neuralgia

doi:10.3969/j.issn.1674-8115.2024.02.008

Abstract

Abstract:

Objective ·To investigate the efficacy and safety of hypertonic dextrose prolotherapy (DPT) in the treatment of postherpetic neuralgia. Methods ·Seventy-eight patients with postherpetic neuralgia who visited the Department of Pain of The Affiliated Hospital of Xuzhou Medical University from June 2019 to December 2022 were selected. The patients were randomly assigned to a control group and a research group in a 1∶1 ratio, with 39 patients in each group. The control group was treated with traditional analgesic solution, while the research group was treated with traditional analgesic solution combined with DPT. Visual analog scale (VAS) was used to evaluate the patients' pain level before and after treatment, flow cytometry was used to measure the patients' T-cell subsets, and enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of C-reactive protein (CRP), interleukin-6 (IL-6), and IL-10 cytokines. The VAS scores were compared between the two groups of patients before and at 1, 2, 4, 8, and 12 weeks after treatment. CD4⁺/CD8⁺, CRP, IL-6, IL-10 levels, and the incidence of adverse reactions before and 2 weeks after treatment were compared between the two groups. Results ·There was no statistically significant difference in sex ratio, age, and disease duration between the two groups of patients. The VAS scores of the two groups of patients at 1, 2, 4, 8, and 12 weeks after treatment were significantly lower than those before treatment, and the differences were statistically significant (all P<0.05). The VAS scores of the research group at 1, 2, 4, 8, and 12 weeks after treatment were significantly lower than those of the control group (all P<0.05). There was no statistically significant difference in basal CD4⁺/CD8⁺, CRP, IL-6 and IL-10 levels between the two groups of patients. IL-6 and CRP levels in the research group were significantly lower after treatment than those in the control group, and the differences were statistically significant (all P=0.000). CD4⁺/CD8⁺ and IL-10 levels were significantly higher in the research group than those in the control group after treatment, and the difference was statistically significant (all P=0.000). No adverse reactions such as local nerve damage, epidural hematoma, infection, pneumothorax or allergy occurred in both groups of patients during the treatment. Conclusion ·DPT can significantly reduce the pain of PHN patients, improve patients' T lymphocyte subpopulations and cytokine expression, and can be safely applied to the clinic.

Key words: hypertonic dextrose prolotherapy (DPT), postherpetic neuralgia (PHN), T cell count, cytokine

CLC Number:

R752.12

YIN Qin, CHEN Liping, XU Heng, YUAN Yan, LIANG Dong, SHEN Wen. Efficacy and safety of hypertonic dextrose prolotherapy for patients with post-herpetic neuralgia[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 223-227.

Figures/Tables 3

TrendMD

References 17

1	TANG J Y, ZHANG Y C, LIU C X, et al. Therapeutic strategies for postherpetic neuralgia: mechanisms, treatments, and perspectives[J]. Curr Pain Headache Rep, 2023, 27(9): 307-319.
2	GIORDANO L, MURRELL W D, MAFFULLI N. Prolotherapy for chronic low back pain: a review of literature[J]. Br Med Bull, 2021, 138(1): 96-111.
3	IGWE N, PATEL N C, AIJAZ T. Regenerative therapy in pain[M]. Treasure Island (FL): StatPearls Publishing, 2023.
4	TSAI S W, HSU Y J, LEE M C, et al. Effects of dextrose prolotherapy on contusion-induced muscle injuries in mice[J]. Int J Med Sci, 2018, 15(11): 1251-1259.
5	BAHGAT M M, ABDEL-HAMID A M. Is dextrose prolotherapy beneficial in the management of temporomandibular joint internal derangement? A systematic review[J]. Cranio, 2023: 1-9.
6	HAN D S, LEE C H, SHIEH Y D, et al. A role for substance P and acid-sensing ion channel 1a in prolotherapy with dextrose-mediated analgesia in a mouse model of chronic muscle pain[J]. Pain, 2022, 163(5): e622-e633.
7	AGGARWAL A, SURESH V, GUPTA B, et al. Post-herpetic neuralgia: a systematic review of current interventional pain management strategies[J]. J Cutan Aesthet Surg, 2020, 13(4): 265-274.
8	LIN C S, LIN Y C, LAO H C, et al. Interventional treatments for postherpetic neuralgia: a systematic review[J]. Pain Physician, 2019, 22(3): 209-228.
9	DENG A S, CHEN Z J, LIN S, et al. Ultrasound-guided thoracic paravertebral block using paraventricular oblique sagittal (POS) approach for the treatment of acute herpes zoster: a two-blind randomized controlled trial[J]. Pain Ther, 2023, 12(3): 797-809.
10	SIT R W S, REEVES K D, ZHONG C C, et al. Efficacy of hypertonic dextrose injection (prolotherapy) in temporomandibular joint dysfunction: a systematic review and meta-analysis[J]. Sci Rep, 2021, 11(1): 14638.
11	WU Y T, CHEN Y P, LAM K H S, et al. Mechanism of glucose water as a neural injection: a perspective on neuroinflammation[J]. Life (Basel), 2022, 12(6): 832.
12	SIT R W S, WU R W K, LING S K K, et al. A protocol for a randomized clinical trial assessing the efficacy of hypertonic dextrose injection (prolotherapy) in chronic ankle instability[J]. Trials, 2022, 23(1): 1063.
13	SEI J J, COX K S, DUBEY S A, et al. Effector and central memory poly-functional CD4⁺ and CD8⁺ T cells are boosted upon ZOSTAVAX^® vaccination[J]. Front Immunol, 2015, 6: 553.
14	SUTHERLAND J P, STEAIN M, BUCKLAND M E, et al. Persistence of a T cell infiltrate in human Ganglia years after herpes zoster and during post-herpetic neuralgia[J]. Front Microbiol, 2019, 10: 2117.
15	FUKUYASU A, KAMATA M, SY HAU C, et al. Serum interleukin-10 level increases in patients with severe signs or symptoms of herpes zoster and predicts the duration of neuralgia[J]. J Dermatol, 2021, 48(4): 511-518.
16	LIN D, ZHONG C Y, JIANG Q L, et al. Serum interleukin-6 levels are increased in post-herpetic neuralgia: a single-center retrospective study[J]. An Bras Dermatol, 2023, 98(2): 202-207.
17	SAXENA A K, BHARDWAJ N, CHILKOTI G T, et al. Modulation of mRNA expression of IL-6 and mTORC1 and efficacy and feasibility of an integrated approach encompassing cognitive behavioral therapy along with pregabalin for management of neuropathic pain in postherpetic neuralgia: a pilot study[J]. Pain Med, 2021, 22(10): 2276-2282.

Time	Control group	Research group	P_{group effect-simple}
Before treatment	7 (5, 8)	6 (6, 7)	0.591
1 week after treatment	4 (3, 4)	4 (3, 4)	0.002
2 weeks after treatment	4 (3, 4)	3 (3, 3)	0.000
4 weeks after treatment	4 (3, 4)	2 (2, 3)	0.000
8 weeks after treatment	4 (3, 4)	2 (2, 2)	0.000
12 weeks after treatment	4 (3, 4)	2 (2, 2)	0.000
P_{time effect-simple}	0.000	0.000	‒

Time	Control group	Research group	P_{group effect-simple}
Before treatment	7 (5, 8)	6 (6, 7)	0.591
1 week after treatment	4 (3, 4)	4 (3, 4)	0.002
2 weeks after treatment	4 (3, 4)	3 (3, 3)	0.000
4 weeks after treatment	4 (3, 4)	2 (2, 3)	0.000
8 weeks after treatment	4 (3, 4)	2 (2, 2)	0.000
12 weeks after treatment	4 (3, 4)	2 (2, 2)	0.000
P_{time effect-simple}	0.000	0.000	‒

Index	Control group	Research group	P value
CRP/(mg·mL^-1)
Before	25.80±3.46	26.10±3.85	0.725
After	10.30±1.57^①	4.70±0.85^②	0.000
IL-6/(pg·mL^-1)
Before	83.80±10.85	86.70±12.44	0.280
After	26.30±3.73^①	11.70±1.49^②	0.000
IL-10/(µg·mL^-1)
Before	0.84±0.16	0.79±0.13	0.115
After	3.90±0.55	11.60±1.50	0.000
CD4⁺/CD8⁺
Before	0.99±0.14	1.04±0.16	0.142
After	1.45±0.19	1.98±0.37	0.000

Index	Control group	Research group	P value
CRP/(mg·mL^-1)
Before	25.80±3.46	26.10±3.85	0.725
After	10.30±1.57^①	4.70±0.85^②	0.000
IL-6/(pg·mL^-1)
Before	83.80±10.85	86.70±12.44	0.280
After	26.30±3.73^①	11.70±1.49^②	0.000
IL-10/(µg·mL^-1)
Before	0.84±0.16	0.79±0.13	0.115
After	3.90±0.55	11.60±1.50	0.000
CD4⁺/CD8⁺
Before	0.99±0.14	1.04±0.16	0.142
After	1.45±0.19	1.98±0.37	0.000

[1]	LI Ziyun, ZHUANG Xinjuan, JI Ye, TIAN Hairong, YIN Jun. Effects of Astragali Radix on T lymphocyte subsets expression in peripheral blood of Hashimoto′s thyroiditis patients with normal thyroid function [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(1): 108-115.
[2]	XU Yinglian, TIAN Jing, ZHANG Xiang, ZHAO Shunying. Research progress in the roles of airway epithelial cells in the pathogenesis of asthma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 619-623.
[3]	WU Ruifang, FENG Ming, MENG Jian. Review of role of fatty acid binding protein-4 in obesity-associated tumors [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1311-1316.
[4]	YANG Wenqian, CHEN Chiqi, ZHAO Lu, CAO Liyuan, XIA Yiqiu, LU Zhigang, ZHENG Junke. Immune inhibitory receptor LILRB2 enhances SARS-CoV-2 spike protein-mediated immune inflammation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1188-1196.
[5]	WEI Xiaowei, TIAN Fuju, LIU Xiaorui, ZENG Weihong, CHEN Cailian, LIN Yi. TCF3 knockdown inhibits the decidualization of human endometrial stromal cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1247-1257.
[6]	LI Xinyu, ZUO Bin, WANG Wen, NIU Xiaoyin, WENG Zhen, HE Yang. Levels of adiponectin in the peripheral blood of patients with immune thrombocytopenia and its effect on the differentiation of megakaryocyte cell line [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 866-874.
[7]	LEI Haitao, TIAN Xuemei, JIN Fangquan. Advances in the correlation between cytokine signal transduction inhibitors and rheumatoid arthritis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 945-951.
[8]	Xiaowen ZHANG, Yi WANG, Chan ZHANG, Di ZHANG, Hang YUN, Di HUANG. Effects of Pcsk9 gene interference on high fat-induced nonalcoholic fatty liver disease with atherosclerosis in rats [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 150-157.
[9]	DONG Yushan, ZHANG Wenjie. Research progress of cytokines in treatment of osteoarthritis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1627-1632.
[10]	Rui CHEN, Yun ZHAO, Xiao-xia ZHAO, Dong MA, Yi-jiang HAN, Deng-ming LAI, Wei-zhong GU, Jin-fa TOU. Expression characteristics of silent information regulator transcript 1 in intestinal tissues of neonatal necrotizing enterocolitis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(9): 1154-1161.
[11]	DAI Fei, WEI Jin-jin, TANG Xin-yue, CHEN Zheng, LIN Lin. Effect of sublingual immunotherapy on functions of effector T cells and regulatory T cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(5): 626-632.
[12]	GAO Han, ZHANG Ping. Research progress on endometriosis-related immune events [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1544-1549.
[13]	WANG Ling-xiao, LIU Ting-ting, YANG Xiao-hui, YAO Zhi-qing, CAI Hui-zhen. Effect of Lycium barbarum polysaccharides on inflammatory cytokines in type 2 diabetes mellitus model mice without myeloid differentiation factor 88 gene [J]. , 2019, 39(2): 136-.
[14]	LIN Hui, CHEN Xi, LIU Xin-mei, HUANG He-feng. Intrauterine high-nutrition induced immunoreaction abnormality in monocytes and nature killer cells in offspring [J]. , 2018, 38(7): 753-.
[15]	LIU Yang-chun, YE Hai-feng, LI Xiao-yan, HU Chuan, HUANG Jian, ZHENG Yue-hui. Regulatory factors and modulation mechanisms of functions of ovarian germline stem cell niche [J]. , 2018, 38(6): 708-.